Serena Di Cosimo

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +14

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

Maurizio Scaltriti, Federico Rojo, Alberto Ocaña et al. · JNCI Journal of the National Cancer Institute · 2007 · 881 citations · Full text

Medicine, Cancer Biology, Oncology +17

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Violeta Serra, Ben Markman, Maurizio Scaltriti et al. · Cancer Research · 2008 · 796 citations · Full text

Medicine, Oncology, Pharmacology +16

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Evandro de Azambuja, Andrew Holmes, Martine Piccart et al. · The Lancet Oncology · 2014 · 455 citations

Medicine, Oncology, Pharmacology +15

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart, Eileen Holmes, José Baselga et al. · Journal of Clinical Oncology · 2015 · 374 citations · Full text

Medicine, Oncology, Pharmacology +17